- Revive Therapeutics (RVV) has joined forces with Supriya to pursue Emergency Use Authorization for Bucillamine to treat COVID-19 in India
- The companies entered into a memorandum of understanding on June 7, 2021 to manufacture the API and register and commercialize the drug
- The company may also expand commercialization globally by leveraging Supriya’s extensive manufacturing and commercial network
- Supriya Lifescience is a manufacturer and supplier of active pharmaceutical ingredients and pharmaceutical products
- Revive Therapeutics is focused on the research and development of therapeutics for infectious diseases and rare disorders
- Revive Therapeutics (RVV) closed the day up 3.53 per cent trading at $0.44 per share
Revive Therapeutics (RVV) has joined forces with Supriya to pursue Emergency Use Authorization for Bucillamine to treat COVID-19 in India.
The companies entered into a memorandum of understanding on June 7, 2021 to manufacture the API and register and commercialize Bucillamine in the hopes of diminishing COVID’s hold on the country.
Revive may also expand commercialization globally by leveraging Supriya’s extensive manufacturing and commercial network, coupled with Revive’s ongoing U.S. FDA Phase 3 clinical study results for Bucillamine as treatment for mild-to-moderate COVID-19.
Michael Frank, CEO of Revive, commented,
“While our Phase 3 clinical study for COVID-19 is ongoing in the USA, we are laying the groundwork by partnering with Supriya to execute on our global manufacturing and commercialization plans, and leveraging their regulatory expertise and commercial reach with 78 countries they currently supply pharmaceutical products to.
We are focused on completing our current Phase 3 study in the USA and also obtaining EUA. These results will support drug approval registrations globally, including India, Europe and Canada.”
Dr. Satish Wagh, CMD, Supriya Lifescience, added,
“Through this collaboration, we aim to join our forces with Revive to accelerate access to Bucillamine in India at a time when it is most needed. With this partnership, Supriya aims to enter into a niche area of chemistry and products thereby bolstering its CMO and research capabilities.”
The companies are not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Based in Mumbai, India, Supriya Lifescience is a manufacturer and supplier of active pharmaceutical ingredients and pharmaceutical products.
Revive Therapeutics is focused on the research and development of therapeutics for infectious diseases and rare disorders.
Revive Therapeutics (RVV) closed the day up 3.53 per cent trading at $0.44 per share.
